Chinese genome editing technologies developer EdiGene Inc. has secured about US$10 million in its series pre-B plus round of financing led by Chinese venture capital firm Green Pine Capital Partners, said EdiGene in a statement released on Monday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?